Cleared Traditional

K952287 - REAADS ANTI-PHOSPHATIDYLSERINE QUANTITATIVE TEST KIT

K952287 is an FDA 510(k) clearance for REAADS ANTI-PHOSPHATIDYLSERINE QUANTITA..., manufactured by Reaads Medical Products, Inc.. The device is a Class 2 Immunology device with product code MID cleared through the Traditional 510(k) pathway after a 216-day FDA review.

K952287 · Reaads Medical Products, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1995
Decision
216d
Days
Class 2
Risk

K952287 is an FDA 510(k) clearance for the REAADS ANTI-PHOSPHATIDYLSERINE QUANTITATIVE TEST KIT. Classified as System, Test, Anticardiolipin Immunological (product code MID), Class II - Special Controls.

Submitted by Reaads Medical Products, Inc. (Westminister, US). The FDA issued a Cleared decision on December 18, 1995 after a review of 216 days - an extended review cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Reaads Medical Products, Inc. devices

FDA 510(k) Submission Details - K952287

510(k) Number K952287 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 16, 1995
Decision Date December 18, 1995
Days to Decision 216 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
111d slower than avg
Panel avg: 105d · This submission: 216d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MID Device Classification - Class 2, Special Controls

Product Code MID System, Test, Anticardiolipin Immunological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MID System, Test, Anticardiolipin Immunological

All 77
Devices cleared under the same product code (MID) and FDA review panel - the closest regulatory comparables to K952287.
CARDIOLIPIN G EIA TEST SYSTEM
K946215 · Hogan & Hartson · Jan 1996
CARDIOLIPIN A EIA TEST SYSTEM
K946216 · Hogan & Hartson · Jan 1996
CARDIOLIPIN M EIA TEST SYSTEM
K946217 · Hogan & Hartson · Jan 1996
VARELISA CARDIOLIPIN ABS SCREEN
K951187 · Elias U.S.A., Inc. · Oct 1995
QUANTA LITE IGA ACA (HRP)
K953366 · Inova Diagnostics, Inc. · Sep 1995
QUANTA LITE ACA SCREEN (HRP)
K953291 · Inova Diagnostics, Inc. · Aug 1995